PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-105.80%
Operating expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-105.80%
Total costs reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
-50.00%
Interest expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
94.20%
EBITDA change of 94.20% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
94.20%
Income change of 94.20% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other expenses reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-94.81%
Tax expense reduction while Biotechnology median is 0.00%. Seth Klarman would investigate advantages.
94.81%
Income change of 94.81% versus flat Biotechnology. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
98.22%
EPS change of 98.22% versus flat Biotechnology. Walter Schloss would verify quality.
98.22%
Diluted EPS change of 98.22% versus flat Biotechnology. Walter Schloss would verify quality.
200.00%
Share count change of 200.00% versus stable Biotechnology. Walter Schloss would verify approach.
200.00%
Diluted share change of 200.00% versus stable Biotechnology. Walter Schloss would verify approach.